Bristol-Myers Squibb Co (NYSE:BMY) Shares Sold by Gilman Hill Asset Management LLC

Gilman Hill Asset Management LLC decreased its holdings in Bristol-Myers Squibb Co (NYSE:BMY) by 2.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 13,925 shares of the biopharmaceutical company’s stock after selling 300 shares during the period. Gilman Hill Asset Management LLC’s holdings in Bristol-Myers Squibb were worth $706,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the business. Garrett Wealth Advisory Group LLC acquired a new stake in shares of Bristol-Myers Squibb during the 3rd quarter worth approximately $26,000. Lenox Wealth Advisors LLC increased its holdings in shares of Bristol-Myers Squibb by 555.7% during the 3rd quarter. Lenox Wealth Advisors LLC now owns 636 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 539 shares during the last quarter. Financial Gravity Wealth Inc. increased its holdings in shares of Bristol-Myers Squibb by 101.2% during the 3rd quarter. Financial Gravity Wealth Inc. now owns 650 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 327 shares during the last quarter. Endurance Wealth Management Inc. increased its holdings in shares of Bristol-Myers Squibb by 119.6% during the 2nd quarter. Endurance Wealth Management Inc. now owns 918 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 500 shares during the last quarter. Finally, HMS Capital Management LLC acquired a new stake in shares of Bristol-Myers Squibb during the 2nd quarter worth approximately $45,000. Institutional investors own 80.25% of the company’s stock.

Bristol-Myers Squibb stock opened at $53.03 on Friday. Bristol-Myers Squibb Co has a fifty-two week low of $42.48 and a fifty-two week high of $55.85. The company has a debt-to-equity ratio of 1.51, a quick ratio of 3.75 and a current ratio of 3.88. The firm has a 50 day moving average price of $49.95 and a 200 day moving average price of $47.19. The company has a market capitalization of $85.75 billion, a PE ratio of 13.32, a price-to-earnings-growth ratio of 1.23 and a beta of 0.72.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, July 25th. The biopharmaceutical company reported $1.18 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.06 by $0.12. Bristol-Myers Squibb had a net margin of 26.14% and a return on equity of 47.63%. The firm had revenue of $6.27 billion during the quarter, compared to the consensus estimate of $6.10 billion. During the same quarter last year, the firm earned $1.01 EPS. The firm’s revenue for the quarter was up 10.0% on a year-over-year basis. As a group, equities research analysts forecast that Bristol-Myers Squibb Co will post 4.28 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, November 1st. Investors of record on Friday, October 4th will be issued a $0.41 dividend. The ex-dividend date is Thursday, October 3rd. This represents a $1.64 annualized dividend and a yield of 3.09%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 41.21%.

In related news, Director Robert J. Bertolini bought 11,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The stock was purchased at an average price of $44.72 per share, for a total transaction of $491,920.00. Following the acquisition, the director now owns 11,397 shares of the company’s stock, valued at $509,673.84. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.13% of the stock is currently owned by company insiders.

A number of brokerages have recently issued reports on BMY. Atlantic Securities upgraded shares of Bristol-Myers Squibb from a “neutral” rating to an “overweight” rating and set a $63.00 price target for the company in a report on Wednesday, August 14th. ValuEngine downgraded shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a report on Saturday. TheStreet upgraded shares of Bristol-Myers Squibb from a “c+” rating to a “b-” rating in a report on Wednesday, September 18th. Bank of America began coverage on shares of Bristol-Myers Squibb in a report on Wednesday. They set a “buy” rating and a $60.00 price target for the company. Finally, JPMorgan Chase & Co. set a $62.00 price target on shares of Bristol-Myers Squibb and gave the stock a “buy” rating in a report on Friday, September 13th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and ten have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $56.53.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

See Also: Golden Cross

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.